Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Is a |
Product containing neomycin (medicinal product) |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Is a |
Bacitracin-containing product in ocular dose form |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Is a |
kombinationspræparater med neomycin |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Is a |
neomycin til topikal anvendelse |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
neomycin til topikal anvendelse |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Bacitracin ophthalmic preparation |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Is a |
bacitracinzink + neomycinsulfat + polymyxin B-sulfat |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Polymyxin B sulfate |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Antiinfektiøst middel til huden |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Zinc bacitracin |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Neomycin sulfate |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Baktericid |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Local anti-infective |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Has manufactured dose form |
Ocular dose form (dose form) |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Is a |
Product containing neomycin in ophthalmic dosage form |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Is a |
polymyxin B-øjensalve |
false |
Inferred relationship |
Some |
|
|
bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
Has manufactured dose form |
Eye ointment |
false |
Inferred relationship |
Some |
|
|